Home › Catalysts
Quarter catalyst calendar
What lands in 4Q 2026, a look ahead to 1Q 2027, and the rest of the next twelve months below that. Dates are the company's own guidance as reported in Biotech Distilled coverage — most are windows rather than fixed days, and each row says which it is. Click any catalyst to read the latest post on it.
Updated November 18, 2026 · 308 events
No catalysts match these filters.
This quarter · dated
40the company named a day or a month; ~ marks an approximate date
- Oct–Nov 2026 IONS Avoid Ionis corporate update material
- Nov 2026 RVMD Buy RASONQUE daraxonrasib corporate update material
- Nov 2026 ANRO Watch COMP360 Compass NDA filing notable
- Nov 2026 CLNN Hold CLNN filing notable
- ~Nov 2026 HRMY Watch WAKIX / MSN License Agreement notable
- Nov 2026 NRXP Spec buy Corporate financials filing notable
- Nov 20, 2026 PMVP Spec buy Rezatapopt topline thesis-defining
- Nov 22, 2026 CAPR Hold Deramiocel PDUFA date thesis-defining
- Nov 28, 2026 PYPD Spec buy D-PLEX₁₀₀ PDUFA date thesis-defining
- Nov 30, 2026 COGT Buy Bezuclastinib + sunitinib GIST PDUFA thesis-defining
- Nov 30, 2026 MLYS Watch Lorundrostat reimbursement notable
- Dec 2026 ADCT Spec buy ZYNLONTA + glofitamab topline thesis-defining
- Dec 2026 KOD Hold KSI-101 Ph3 topline thesis-defining
- Dec 2026 MLTX Watch Sonelokimab HS PDUFA date thesis-defining
- Dec 2026 ABSI Hold ABS-201 AGA interim major
- Dec 2026 SPRB Hold TA-ERT tralesinidase alfa BLA filing major
- Dec 2026 ADCT Spec buy ZYNLONTA monotherapy MZL readout material
- Dec 2026 CGEM Buy CLN-978 readout material
- Dec 2026 IMUX Spec buy ENSURE-1/ENSURE-2 topline material
- Dec 2026 ZNTL Buy Azenosertib China decision material
- Dec 2026 ALT Buy AUD program corporate update notable
- Dec 2026 CGON Buy CORE-008 Cohort CX / BOND-003 notable
- Dec 2026 CNTB Avoid Rademikibart FDA feedback notable
- Dec 2026 ELVN Watch ELVN-001 relcobatinib interim notable
- Dec 2026 NRSN Avoid PrimeC filing notable
- Dec 1, 2026 TLX Watch ITM acquisition strategic review notable
- Dec 4, 2026 CMMB Avoid Chemomab/Scipher merger vote strategic review notable
- Dec 9, 2026 PRQR Spec buy AX-0810 Ph1 readout major
- Dec 12, 2026 ANAB Spec buy Imsidolimab FDA approval material
- Dec 12, 2026 VNDA Watch Imsidolimab FDA approval material
- Dec 12, 2026 AUTL Spec buy AUTO8 readout notable
- Dec 14, 2026 RLAY Watch Zovegalisib ReInspire readout material
- Dec 14, 2026 IMNM Spec buy IM-1021 ADC interim notable
- Dec 14, 2026 SLS Spec buy SLS009 Tambiciclib readout notable
- Dec 18, 2026 CTNM Watch WuXi AppTec / BIOSECURE FDA material
- Dec 22, 2026 MLYS Watch Lorundrostat FDA decision thesis-defining
- Dec 22, 2026 OCGN Avoid Proposal 1 vote FDA decision material
- Dec 23, 2026 LEGN Hold anito-cel Arcellx PDUFA date thesis-defining
- ~Dec 29, 2026 TLSA Avoid Intranasal foralumab MSA FDA decision material
- Dec 30, 2026 COGT Buy Bezuclastinib NonAdvSM PDUFA date thesis-defining
This quarter · guided to 4Q 2026
57
committed to the quarter, no finer date given
- 4Q 2026 BIOA Hold BGE-102 topline thesis-defining
- 4Q 2026 ZBIO Spec buy Obexelimab SLE Ph2 topline thesis-defining
- 4Q 2026 CLRB Avoid CLR 125 Ph1 interim major
- 4Q 2026 GPCR Hold aleniglipron Ph2 topline major
- 4Q 2026 QUIT Watch Cytisinicline smoking cessation NDA filing major
- 4Q 2026 VYGR Watch VY7523 interim major
- 4Q 2026 ACRV Hold ACR-368 Phase 2b EC Ph2b material
- 4Q 2026 ANNX Watch Tanruprubart BLA filing material
- 4Q 2026 BBOT Hold BBO-11818 Ph1 interim material
- 4Q 2026 BIOA Hold QUELL-CV topline material
- 4Q 2026 CAMP Watch CMP-002 trial start material
- 4Q 2026 CMPX Avoid Tovecimig BLA filing material
- 4Q 2026 IPSC Spec buy CNTY-813 IND filing material
- 4Q 2026 MBX Watch MBX 4291 Ph1 interim material
- 4Q 2026 NVCT Spec buy NXP200 U.S. IND filing material
- 4Q 2026/1Q 2027 QUIT Watch Sopharma arbitration corporate update material
- 4Q 2026 RCUS Buy quemliclustat Ph3 interim material
- 4Q 2026 SLS Spec buy SLS009 AML Ph2 topline material
- 4Q 2026 SMMT Hold ivonescimab NSCLC interim material
- 4Q 2026 SNDX Buy Revuforj 4Q26 revumenib readout material
- 4Q 2026 SNDX Buy BEAT AML, SAVE, 708 intensive-chemo material
- 4Q 2026 TARA Spec buy IV Choline Chloride Ph3 interim material
- 4Q 2026 WVE Hold AATD program Ph1 readout material
- 4Q 2026 ACRS Watch ATI-9494 IND filing notable
- 4Q 2026 ALDX Avoid FDRR appeal corporate update notable
- 4Q 2026 ALMS Watch Envudeucitinib psoriasis Ph2 readout notable
- 4Q 2026 ARVN Watch ARV-806 KRAS readout notable
- 4Q 2026 BCAX Watch Ficerafusp alfa enrollment done notable
- 4Q 2026 CGEM Buy CLN-049 Ph2 readout notable
- 4Q 2026 CMPX Avoid CTX-8371 Ph1 readout notable
- 4Q 2026 CMPX Avoid CTX-10726 Ph1 readout notable
- 4Q 2026 COGT Buy CGT1815 pan-KRAS Inhibitor IND filing notable
- 4Q 2026 COGT Buy CGT1145 IND filing notable
- 4Q 2026 CUE Spec buy CUE-221 Ph2b start notable
- 4Q 2026 EWTX Watch EDG-7500 Ph3 start notable
- 4Q 2026 GLUE Buy MRT-8102 GFORCE-3 Ph2 start notable
- 4Q 2026 GLUE Buy MRT-9347 IND filing notable
- 4Q 2026 GPCR Hold ACCG-3535 / combination trial Ph1 notable
- 4Q 2026 IBRX Hold QUILT-2.005 sBLA filing notable
- 4Q 2026 INBX Hold Ozekibart FDA feedback notable
- 4Q 2026 KZIA Watch Paxalisib HR trial start notable
- 4Q 2026 MBRX Avoid Annamycin filing notable
- 4Q 2026 RAPP Watch RAP-219 FOS interim notable
- 4Q 2026 RCUS Buy ARC-20 cohorts cas+axitinib trial start notable
- 4Q 2026 RCUS Buy PEAK-20 trial start notable
- 4Q 2026 REPL Buy RP2 readout notable
- 4Q 2026 RNTX Watch LTI-03 Ph2 interim notable
- 4Q 2026 SABS Spec buy SAB-142 enrollment done notable
- 4Q 2026 SCYX Watch SCY-770 Ph2 start notable
- 4Q 2026 TARA Spec buy TARA-002 NMIBC enrollment done notable
- 4Q 2026 VERA Buy Atacicept PIONEER Ph2 readout notable
- 4Q 2026 VYGR Watch VY1706 trial start notable
- 4Q 2026 WVE Hold WVE-008 filing notable
- 4Q 2026 ZBIO Spec buy ZB021 Ph1 readout notable
- late 4Q 2026 SLDB Spec buy SGT-003 FDA feedback thesis-defining
- late 4Q 2026 ABVX Watch Obefazimod NDA filing material
- late 4Q 2026 GUTS Avoid Revita filing notable
Could land this quarter — no finer guidance
38
a six- to twelve-month window that overlaps this quarter by construction; shown in full on each company's page
- 2026 BCTX Avoid Bria-IMT + CPI Ph3 interim major
- 2026 NKTX Spec buy NKX019 Ntrust-1 readout major
- 2026 SANA Watch SC451 T1D IND filing material
- 2026 IMTX Hold IMA402 Ph1 interim notable
- 2026 KYTX Hold Miv-cel Ph1 readout notable
- 2026 STRO Buy STRO-006 IND filing notable
- 2H 2026 GNLX Watch Olvi-Vec OnPrime Ph3 topline thesis-defining
- 2H 2026 RXRX Watch REC-4881 FDA feedback thesis-defining
- 2H 2026 BBOT Hold BBOT pipeline BBO-11818 Ph1 readout major
- 2H 2026 INAB Watch INB-400 FDA feedback major
- 2H 2026 CRVO Avoid Neflamapimod RESTORE topline material
- 2H 2026 ERAS Watch ERAS-4001 Ph1 interim material
- 2H 2026 ANNX Watch ANX1502 POC readout notable
- 2H 2026 ARVN Watch ARV-393 Ph1 interim notable
- 2H 2026 INSM Watch ARIKAYCE Japan filing notable
- 2H 2026 PALI Watch PALI-2108 CD IND filing notable
- 2H 2026 QNRX Hold QRX003 Ph2 readout notable
- 2H 2026 QNRX Hold QRX003 PSS Ph2 start notable
- 2H 2026 STRO Buy STRO-227 IND filing notable
- 2H 2026 VIR Buy VIR-5818 Ph1 readout notable
- 2H 2026 ZBIO Spec buy Obexelimab MAA filing notable
- by the end of 2026 or early 2027 IDYA Watch IDE849 Ph1 topline thesis-defining
- by year-end 2026 KYMR Buy KT-621 BROADEN2 Ph2b topline thesis-defining
- year-end 2026 APVO Avoid Mipletamig Ph2 readout major
- year-end 2026 BEAM Spec buy risto-cel BLA filing major
- late 2026 CLDX Buy Barzolvolimab Atopic Dermatitis Ph2 topline major
- By year-end 2026: PIKture-01 "mature data" OKUR Watch OKI-219 readout major
- year-end 2026 / Q1 2027 TGTX Watch SubQ formulation Ph3 topline major
- Year-end 2026 NAMS Watch RUBENS obicetrapib Ph3 topline material
- By YE2026 RLAY Watch Zovegalisib 1L combo FDA feedback material
- ~YE 2026 XNCR Buy XmAb942 UC interim material
- by the end of 2026 ARDX Avoid Tenapanor ACCEL enrollment done notable
- near the end of 2026 or early 2027 ETON Buy Amglidia NDA filing notable
- Late 2026 INAB Watch INB-100 enrollment done notable
- By year-end 2026 IRON Buy Bitopertin filing notable
- before the end of this year QTTB Watch Bempikibart FDA feedback notable
- year-end 2026 RLMD Watch NDV-01 IND filing notable
- YE 2026 SNDX Buy SNDX-4321 EGFR IND filing notable
Next quarter · 1Q 2027 preview
88
quarter-precision or finer
- 1Q 2027 ANNX Watch Vonaprument Ph3 topline thesis-defining
- 1Q 2027 BMEA Avoid Icovamenib topline thesis-defining
- 1Q 2027 BMEA Avoid Icovamenib COVALENT-211 topline thesis-defining
- 1Q 2027 CBIO Buy CR-001 Ph1 topline thesis-defining
- 1Q 2027 IRD Hold OPGx-BEST1 4.5e9 vg Ph3 topline thesis-defining
- 1Q 2027 MBRX Avoid Annamycin topline thesis-defining
- 1Q 2027 OCGN Avoid OCU400 Ph3 topline thesis-defining
- 1Q 2027 OLMA Avoid Palazestrant topline thesis-defining
- 1Q 2027 PMN Watch PMN310 topline thesis-defining
- 1Q 2027 RNAC Buy Descartes-08 AURORA topline thesis-defining
- 1Q 2027 SEPN Watch SEP-479 Ph1 topline thesis-defining
- Jan 2027 TECX Watch TX45 topline thesis-defining
- 1Q 2027 TTRX Hold GX-03 eczema Ph2 topline thesis-defining
- 1Q 2027 XENE Hold Azetukalner MDD Ph3 topline thesis-defining
- ~Jan–Mar 2027 ABVX Watch Obefazimod FDA decision major
- 1Q 2027 AKTS Buy AKY-1189 Ph1 interim major
- 1Q 2027 AXSM Avoid solriamfetol ENGAGE Ph3 topline major
- 1Q 2027 CGEN Watch COM701 interim major
- 1Q 2027 GUTS Avoid Revita pivotal topline major
- 1Q 2027 NAMS Watch PREVAIL obicetrapib readout major
- 1Q 2027 NKTR Watch Rezpegaldesleukin AD readout major
- 1Q 2027 OLMA Avoid OPERA-01 topline major
- Jan 2027 PRQR Spec buy AX-0811 Ph1 interim major
- 1Q 2027 SRPT Spec buy ELEVIDYS readout major
- 1Q 2027 SRPT Spec buy ELEVIDYS ENDEAVOR readout major
- 1Q 2027 AARD Avoid ARD-101 FDA feedback material
- 1Q 2027 ACET Watch Prula-cel interim material
- 1Q 2027 ALMS Watch Zasocitinib Takeda FDA decision material
- 1Q 2027 CBIO Buy CR-003 / SKB105 Ph1 readout material
- Jan 2027 CTMX Spec buy Varseta-M (CX-2051) mCRC monotherapy Phase material
- 1Q 2027 DYN Buy z-basivarsen pivotal topline material
- 1Q 2027 EXEL Hold STELLAR-304 topline material
- 1Q 2027 GANX Avoid GT-02287 Ph2 start material
- 1Q 2027 LENZ Hold VIZZ China decision material
- 1Q 2027 MLTX Watch Sonelokimab PsA topline material
- 1Q 2027 MLTX Watch Sonelokimab HS topline material
- 1Q 2027 NAMS Watch PREVAIL obicetrapib interim material
- Jan 2027 PEPG Buy PGN-EDODM1 interim material
- 1Q 2027 PMVP Spec buy Rezatapopt NDA filing material
- 1Q 2027 TECX Watch TX45 readout material
- Jan 2027 TNGX Buy Vopimetostat monotherapy lung cancer Ph1 material
- Jan 2027 TNGX Buy TNG456 Ph1 interim material
- 1Q 2027 VIR Buy ECLIPSE 2 and 3 topline material
- ~1Q 2027 VOR Spec buy RemeGen warrants FDA approval material
- 1Q 2027 AVBP Watch firmonertinib readout notable
- 1Q 2027 CRVO Avoid nfvPPA 80 mg BID UK notable
- Jan 2027 ETON Buy ASN-001 NDA filing notable
- 1Q 2027 INBX Hold Ozekibart interim notable
- 1Q 2027 KZIA Watch Paxalisib colorectal Ph2 start notable
- 1Q 2027 MBX Watch Septerna SEP-479 readout notable
- 1Q 2027 MGTX Watch Bota-vec BLA filing notable
- 1Q 2027 ONCY Avoid REO 033 Part B trial notable
- early 1Q 2027 PTGX Hold PN-881 Ph2b start notable
- 1Q 2027 PTGX Hold PN-8047 Ph1 start notable
- 1Q 2027 PTGX Hold Silence Therapeutics acquisition by Merck notable
- 1Q 2027 RAPP Watch RAP-219 bipolar mania FDA feedback notable
- 1Q 2027 SEPN Watch SEP-204 Ph1 start notable
- 1Q 2027 SLDB Spec buy SGT-212 Ph1 readout notable
- 1Q 2027 SNDX Buy Niktimvo cGVHD axatilimab Ph2 readout notable
- 1Q 2027 STOK Watch Zorevunersen NDA filing notable
- 1Q 2027 TLSA Avoid Intranasal foralumab Alzheimer's Ph2 readout notable
- Jan 10, 2027 ETON Buy VALTOCO / LIBERVANT 12+ FDA material
- Jan 21, 2027 DYN Buy z-rostudirsen FDA decision major
- Jan 26, 2027 HRMY Watch '920 patent case interim notable
- Jan 28, 2027 INSM Watch ARIKAYCE FDA approval thesis-defining
- Jan 30, 2027 ABVX Watch Roche afimkibart AMETRINE-1 readout notable
- Feb 1, 2027 AGIO Watch Mitapivat sNDA SCD FDA approval thesis-defining
- Feb 2027 ORIC Watch Mevrometostat MEVPRO-1 Pfizer topline thesis-defining
- ~Feb 2027 ALMS Watch Envudeucitinib psoriasis PDUFA date major
- Feb 2027 INMB Watch CORDStrom/Ebstrocel MAA filing major
- Feb 1, 2027 DBVT Watch Fareva Amboise factory FDA decision material
- Feb 2027 ENTA Watch EDP-978 Ph1 topline material
- Feb 2027 IRON Buy Dersimelagon LEO PDUFA date material
- Feb 2027 – Sep 2028 PTGX Hold ICOTYDE readout material
- Feb 2027 HRMY Watch '197/'947 patents AET litigation ruling notable
- Feb 2027 LQDA Spec buy YUTREPIA SSc-RP readout notable
- Feb 12, 2027 BLTE Spec buy tinlarebant PDUFA date material
- Feb 27, 2027 CGEM Buy Zipalertinib EGFR FDA decision major
- Feb 27, 2027 AVBP Watch zipalertinib PDUFA date material
- Mar 2027 CGON Buy BCG-unresponsive BLA filing notable
- Mar 2027 CRVS Buy Soquelitinib AD Ph3 interim notable
- Mar 2027 NRSN Avoid NDS Canada filing notable
- ~Mar 2027 STOK Watch Zorevunersen corporate update notable
- late 1Q 2027 TYRA Watch BEACH301 ACH readout notable
- Mar 3, 2027 EXEL Hold Zanzalintinib FDA approval material
- Mar 10, 2027 NTLA Spec buy lonvo-z HAE PDUFA date thesis-defining
- Mar 29, 2027 ETON Buy LIBERVANT PDUFA date thesis-defining
- Mar 31, 2027 MLYS Watch Lorundrostat Tranche B financing notable
Further out · through 4Q 2027
123
the rest of the next twelve months, held to the same bar: quarter-precision or finer, or a wider window an outside source has confirmed
- Early 2027 ABSI Hold ABS-201 AGA topline thesis-defining
- 1H 2027 CHRS Avoid Casdozokitug Ph2 topline thesis-defining
- Early 2027 DRTS Spec buy Alpha DaRT SCC pivotal topline thesis-defining
- 2027 IONS Avoid Obudanersen Ph3 topline thesis-defining
- 1H 2027 LBRX Watch NOVA-2 LB-102 schizophrenia topline thesis-defining
- 2027 RNTX Watch LTI-03 topline thesis-defining
- 1H 2027 VOR Spec buy telitacicept Ph3 topline thesis-defining
- 1H 2027 ZNTL Buy Azenosertib topline thesis-defining
- 2027 ANTX Watch Epetraborole PV interim major
- 1H 2027 IMTX Hold anzu-cel SUPRAME Ph3 interim major
- 1H 2027 MAZE Watch MZE829 readout major
- 1H 2027 RARE Buy DTX301 OTC topline major
- 2027 RVMD Buy RASolve 301 daraxonrasib topline major
- 1H 2027 VOR Spec buy UPSTREAM MG Ph3 topline major
- 1H 2027 ZURA Avoid Tibulizumab TibuSURE topline major
- 1H 2027 CTMX Spec buy CX-801 Ph1 readout material
- 1H 2027 CTMX Spec buy CX-801 readout material
- 2027 DBVT Watch Viaskin Peanut Toddlers 1-3yo BLA material
- 2027 DBVT Watch Toddler BLA ages 1-3 filing material
- 2027 JBIO Spec buy JADE201 Ph1 interim material
- 1H 2027 NVCT Spec buy NXP900 Ph1 readout material
- 1H 2027 PCVX Buy VAX-31 infant Ph2 topline material
- 1H 2027 PEPG Buy PGN-EDODM1 readout material
- 1H 2027 RXRX Watch REC-4881; REC-617; REC-3565 interim material
- 1H 2027 SANA Watch SG293 CAR-T readout material
- 1H 2027 SANA Watch SG293 readout material
- 1H 2027 TLX Watch TLX597-Tx PSMA topline material
- 1H 2027 ARVN Watch ARV-027 polyQ-AR readout notable
- 1H 2027 ENTX Watch EB612 IND filing notable
- 1H 2027 GLUE Buy MRT-8102 GFORCE-2 Ph2 start notable
- 2027 IDYA Watch IDE034 Ph1 interim notable
- 1H 2027 QTTB Watch Bempikibart Ph3 start notable
- 1H 2027 VNDA Watch Bysanti™ milsaperidone readout notable
- 1H 2027 XNCR Buy XmAb412 Ph1 interim notable
- 2Q 2027 FDMT Watch 4D-150 AMD Ph3 topline thesis-defining
- 2Q 2027 IMCR Spec buy Tebentafusp TEBE-AM topline thesis-defining
- 2Q 2027 BMEA Avoid Icovamenib COVALENT-212 topline major
- 2Q 2027 ADCT Spec buy ZYNLONTA + rituximab FL readout material
- 2Q 2027 CGON Buy Intermediate-risk / HG Ta NMIBC material
- Apr 1, 2027 HRMY Watch Pitolisant GR PDUFA date material
- 2Q 2027 INMB Watch CORDStrom/Ebstrocel BLA filing material
- Apr 2027 LQDA Spec buy Tyvaso UTHR FDA decision material
- 2Q 2027 QNRX Hold QRX003 topline material
- 2Q 2027 ENTA Watch STAT6 IND filing notable
- 2Q 2027 INMB Watch BLA filing notable
- ~Apr 1, 2027 TLSA Avoid Intranasal foralumab MSA readout notable
- Apr 14, 2027 INBX Hold Ozekibart chondrosarcoma BLA PDUFA date major
- Apr 28, 2027 IMNM Spec buy Varegacestat FDA decision major
- Apr 30, 2027 LQDA Spec buy Settlement payments corporate update notable
- mid-2027 CRDL Avoid CardiolRx MAVERIC topline thesis-defining
- mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- by mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- mid-2027 IMMX Buy NXC-201 Ph2 topline thesis-defining
- mid-2027 INMB Watch CORDStrom/Ebstrocel EU decision thesis-defining
- May 1, 2027 QURE Watch AMT-130 ifezuntirgene inilparvovec PDUFA date thesis-defining
- mid-2027 VRCA Spec buy YCANTH (VP-102) common warts topline thesis-defining
- May 1, 2027 AXSM Avoid AXS-12 reboxetine PDUFA date major
- Mid-2027 BCAX Watch Ficerafusp alfa interim major
- in the middle of 2027 CADL Avoid aglatimagene besadenovec BLA filing major
- Mid-2027 CCCC Buy cemsidomide + elranatamab Ph1 readout major
- May 2027 CTNM Watch Admilparant (BMS) ALOFT-IPF full data major
- Mid-2027 IRON Buy Bitopertin FDA decision major
- mid-2027 VSTM Buy Avutometinib + defactinib RAMP Ph3 major
- mid-2027 VTVT Spec buy CATT1 Ph3 topline major
- mid-2027 ABSI Hold ABS-201 Endometriosis Ph2 start notable
- mid-2027 IMMX Buy NXC-201 BLA filing notable
- May 8, 2027 MBX Watch BridgeBio encaleret FDA decision material
- May 12, 2027 PTN Avoid Series J Warrants corporate update notable
- May 27, 2027 ZBIO Spec buy Obexelimab FDA approval material
- May 28, 2027 ETON Buy KHINDIVI FDA approval major
- late 2Q 2027 QUIT Watch Cytisinicline smoking cessation FDA approval thesis-defining
- Jun 2027 ELVN Watch ELVN-001 relcobatinib readout notable
- Jun 29, 2027 COGT Buy Bezuclastinib AdvSM PDUFA date thesis-defining
- Jun 29, 2027 IVVD Avoid PEMGARDA FDA decision major
- 2H 2027 ARDX Avoid Tenapanor ACCEL Ph3 topline thesis-defining
- 3Q 2027 CRVS Buy Soquelitinib Atopic Dermatitis Ph2 topline thesis-defining
- 2H 2027 INKT Watch agenT-797 topline thesis-defining
- 2H 2027 LXEO Spec buy LX2006 FA pivotal topline thesis-defining
- 2H 2027 MPLT Hold ML-007C-MA VISTA Ph2 topline thesis-defining
- 2H 2027 NGNE Spec buy NGN-401 topline thesis-defining
- 2H 2027 OVID Spec buy OV329 topline thesis-defining
- 2H 2027 PALI Watch PALI-2108 UC topline thesis-defining
- 2H 2027 SABS Spec buy SAB-142 topline thesis-defining
- 2H 2027 SCYX Watch SCY-770 Ph2 topline thesis-defining
- 3Q 2027 STOK Watch Zorevunersen topline thesis-defining
- ~2H 2027 XNCR Buy XmAb942 UC topline thesis-defining
- 2H 2027 AGIO Watch Etavopivat Novo Nordisk FDA decision major
- 2H 2027 AXSM Avoid solriamfetol SUSTAIN Ph3 topline major
- 2H 2027 BCYC Watch Zelenectide pevedotin Ph2 readout major
- 2H 2027 BIOA Hold BGE-102 DME Ph1 topline major
- 2H 2027 CABA Hold myositis program DM pivotal topline major
- 3Q 2027 GOSS Watch seralutinib PAH FDA approval major
- 2H 2027 HURA Avoid IFx-2.0 Ph3 topline major
- 2H 2027 IPSC Spec buy CNTY-813 topline major
- 3Q 2027 KPRX Avoid KIO-301 topline major
- 2H 2027 SGMT Spec buy denifanstat AURORA Ph3 topline major
- ~Jul–Dec 2027 ABVX Watch Obefazimod PDUFA date material
- 3Q 2027 CAMP Watch Zorevunersen Stoke Ph3 topline material
- 2H 2027 CBIO Buy CR-001 + Kelun-Biotech ADCs combination material
- 3Q 2027 SYRE Hold SKYLINE Part B topline material
- Jul 2027 KZIA Watch Paxalisib TNBC enrollment done notable
- 3Q 2027 NRSN Avoid PrimeC Ph3 start notable
- 3Q 2027 NRSN Avoid PARAGON trial start notable
- 2H 2027 QTTB Watch Bempikibart readout notable
- 3Q 2027 RAPP Watch RAP-219 LAI long-acting injectable Ph1 notable
- 2H 2027 REPL Buy RP1 interim notable
- 2H 2027 STOK Watch Zorevunersen NDA filing notable
- 3Q 2027 SYRE Hold SPY120/SPY130/SPY230 combinations + all monotherapies notable
- 2H 2027 TARA Spec buy TARA-002 BLA filing notable
- ~Jul 2027 TLSA Avoid Intranasal foralumab ALS readout notable
- Jul 16, 2027 EVMN Watch EVO756 topline major
- Late-2027 KYMR Buy KT-621 BREADTH Ph2b topline thesis-defining
- Late 2027 (guided): REBOUND topline ANTX Watch Epetraborole REBOUND topline major
- end of 2027 TENX Watch TNX-103 enrollment done notable
- Sep 30, 2027 MLYS Watch Lorundrostat loan covenant corporate update notable
- Oct 2027 AUTL Spec buy BOBCAT MS Ph1 interim major
- 4Q 2027 ORIC Watch Mevrometostat MEVPRO-2 Pfizer topline major
- Oct 2027 AUTL Spec buy BOBCAT MS Ph2 readout material
- 4Q 2027 HROW Avoid G-MELT FDA approval material
- 4Q 2027 MESO Avoid Ryoncil adult SR-aGvHD interim material
- 4Q 2027 PALI Watch ASCENTRA-UC readout material
- 4Q 2027 ENTA Watch MRGPRX2 IND filing notable
- ~Oct 2027 QUIT Watch Cytisinicline vaping cessation Ph3 start notable
How to read this
Deeper blue means more of the thesis turns on the event — not a view on the stock and not a prediction of the outcome. A thesis-defining readout and a routine trial start are both just events until they report.
Dates reflect company guidance as reported in Biotech Distilled coverage and are frequently windows rather than fixed dates. Not investment advice.